The mechanisms underpinning the benefits of GLP-1 RAs on renal outcomes could be attributed to the presence of GLP-1 receptors in the renal glomeruli and mesangial cells, attenuating the inflammatory response to advanced glycation end products and reducing the progression of diabetic kidney disease [137]. Here, GLP1R is linked to diabetic kidney disease.